Skip to content
Search

Latest Stories

Submit Guest Post

Analysts upbeat about IPO-bound Oxford Nanopore's valuation

Analysts upbeat about IPO-bound Oxford Nanopore's valuation

AS Oxford Nanopore confirmed its plans for stock market floatation later this year, market analysts are upbeat about its potential valuation.

The biotech company was valued at £2.4 billion when it raised £195 million in May this year and analysts at Jefferies believe it has the potential to reach a valuation of £3.9bn.


Oxford Nanopore would have “scarcity value” as one of the few biotech companies listing on London's stock market, Julian Roberts of Jefferies told The Telegraph.

He said the company, which is yet to make profits, could have fetched a higher valuation if it were to list on the Nasdaq.

In a filing to the London Stock Exchange, the genome sequencing company said it intends to have a free float of “at least 25 per cent” of its share capital.

The initial public offering (IPO) would comprise new shares to be issued by the company and an offer of existing shares, it said.

Among the potential risks, the biotech company warned that rivals could attempt to call into question the reputation of its chief executive Gordon Sanghera.

Referring to a patent case in an American court involving Sanghera, the company said, “litigation counterparties will attempt to impugn the integrity of the group and/or its management when involved in intellectual property litigation”.

When Sanghera was director of research and development for the diabetes vertical of Abbott Laboratories, a California court judge found him guilty of inequitable conduct, The Times reported.

It was found in 2008 that there was “materially misleading omission” in his direct representations to the US Patent and Trademark Office.

Sanghera, 60, holds 10.4 million shares in Oxford Nanopore.

Based at the Oxford Science Park, it also has offices in Shanghai, Beijing and San Francisco, employing more than 600 people, 500 of them in the UK.

Founded in 2005 as a spin-out from the University of Oxford, the company provides DNA/RNA sequencing technology for biomedical, pathogen, plant and animal scientific research, infectious diseases and food and agriculture sectors.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

ABA Finalist

Asian Business Awards 2026 Finalist

AMG

Asian Business Awards 2026 finalists announced

The moment the business community has been waiting for has finally arrived. The final list for the Asian Business Awards 2026 has been unveiled, and it is every bit as impressive as anticipated. Forty-eight exceptional entrepreneurs, executives, founders and innovators have earned their place on this year’s shortlist, setting the stage for one of the most competitive editions in the awards’ history.

Now in its 27th year, the Asian Business Awards have built a reputation as the standout business event of the year, recognising exceptional leaders and outstanding companies across every major sector. Being named on the final list is an achievement in itself, a mark of distinction that places each finalist among the very best of Asian enterprise in Britain.

Keep ReadingShow less